Study met primary endpoint (p=0.000039); VYVGART® Hytrulo demonstrated 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in risk of relapse versus placebo IgG.
MIL-OSI: Zai Lab Announces First Patient Treated in Mainland China for the Global Phase 3 FORTITUDE-101 Study of Bemarituzumab in First-Line Gastric Cancer foreignaffairs.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from foreignaffairs.co.nz Daily Mail and Mail on Sunday newspapers.
SHANGHAI, China and CAMBRIDGE, Mass., July 14, 2023 Zai Lab Limited today announced that the first patient has been treated in the mainland China portion of the global registrational, Phase 3.
SHANGHAI, China and CAMBRIDGE, Mass., July 10, 2023 Zai Lab Limited today announced that China’s National Medical Products Administration has accepted the Biologics License Application .
Zai Lab Announces Promotion of Yajing Chen to Chief Financial Officer tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.